The Rise and Restructuring of BioNTech: Navigating Beyond the Vaccine Spotlight
BioNTech is transitioning from COVID-19 vaccines to innovative cancer therapies using mRNA technology, aiming for market launch by 2026. Revenue dropped from €3.8 billion in 2023 to €2.75 billion in…